James Crowe

Researchers developing potential coronavirus antibody therapies

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

VUMC-led team isolates antibody that blocks bird flu

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.

New target to stop Ebola

A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.

Alphavirus “Achilles heel”

Targeting the protein that mosquito-borne viruses use to enter cells could be a strategy for preventing infection by multiple emerging viruses.

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

Computer illustration of a plasma cell (B-cell, left) secreting antibodies (white) against influenza viruses (right). Antibodies bind to specific antigens, for instance viral proteins, marking them for destruction by phagocyte immune cells.

Flu Fighter: Dr. James Crowe is leading a global effort to take the guesswork out of the flu shot

From Vanderbilt Magazine: James Crowe, director of the Vanderbilt Vaccine Center, hopes to create a universal flu vaccine–permanently eliminating the problem of ineffective or under-effective annual flu shots.

1 2